Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Prepaid Assets (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Prepaid Assets for 12 consecutive years, with $4.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Prepaid Assets rose 22.28% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Sep 2025, up 22.28%, and an annual FY2024 reading of $3.6 million, down 28.35% over the prior year.
  • Prepaid Assets was $4.0 million for Q3 2025 at CytomX Therapeutics, down from $4.7 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $7.5 million in Q4 2022 and bottomed at $3.1 million in Q2 2024.
  • Average Prepaid Assets over 5 years is $4.5 million, with a median of $4.3 million recorded in 2021.
  • The sharpest move saw Prepaid Assets crashed 43.51% in 2021, then soared 74.24% in 2022.
  • Year by year, Prepaid Assets stood at $4.3 million in 2021, then soared by 74.24% to $7.5 million in 2022, then plummeted by 33.1% to $5.0 million in 2023, then fell by 28.35% to $3.6 million in 2024, then increased by 10.7% to $4.0 million in 2025.
  • Business Quant data shows Prepaid Assets for CTMX at $4.0 million in Q3 2025, $4.7 million in Q2 2025, and $4.8 million in Q1 2025.